Compounded GLP-1 Payments: Why Processors Drop Semaglutide Clinics
Compounded semaglutide payment processing is high risk. Learn why GLP-1 telehealth clinics get terminated and how to keep a stable merchant account.
Photo: Pixabay
On this page 8 sections
- Why Compounded Semaglutide Payment Processing Is Under Scrutiny
- How FDA Shortage Changes Affect Semaglutide and Tirzepatide Merchant Accounts
- Marketing Claims That Trigger Card Network Reviews
- Compounding Pharmacy Partners: What Underwriters Ask
- Subscription Billing Risks in Weight-Loss Telehealth Payment Processing
- What to Do When Your Processor Terminates You
- Building a Backup Plan for Your GLP-1 Telehealth Merchant Account
- Next Steps for Compounded GLP-1 Clinics
Key takeaways
- Processors reassess compounded GLP-1 sellers when FDA shortage status changes, because the legal basis for some compounding can change with it.
- Marketing that blurs compounded drugs with brand-name products, or promises results, draws card network and acquirer scrutiny.
- Underwriters want named pharmacy partners, documented prescriber workflows, and subscription terms that are easy to understand and easy to cancel.
- Documenting everything, refunding cleanly, and reapplying honestly gives you the best chance of finding new processing. Workarounds that hide your business make it worse.
If your weight-loss telehealth brand sells compounded GLP-1 medications, compounded semaglutide payment processing is probably the most fragile part of your business. Clinics that processed for months without trouble can get a termination notice with little warning, often soon after a regulatory change they had nothing to do with. This guide covers why processors reassess these programs and how FDA shortage changes reach your merchant account. It also covers the marketing, pharmacy, and billing practices underwriters examine, what to do after a termination, and how to build a backup plan that holds up.
This article is general information, not legal or regulatory advice. Compounding rules, telehealth prescribing rules, and state pharmacy laws change. Confirm your program's status with qualified healthcare regulatory counsel.
Why Compounded Semaglutide Payment Processing Is Under Scrutiny
Most acquirers already treat telehealth as a high-risk category. It combines card-not-present transactions, prescription products, recurring billing, and regulatory exposure. Our guide on why telehealth merchant accounts are classified as high risk covers the baseline, and our guide to accepting HSA and FSA cards for telehealth visits and prescriptions explains why those cards decline. Compounded GLP-1 programs add several risks of their own:
- Regulatory dependency. Whether a pharmacy may compound a version of a commercially available drug can depend on that drug's shortage status and on the type of pharmacy. When that status changes, a processor has to ask whether your product is still lawful to sell in its current form.
- Brand and network exposure. Card networks hold acquirers responsible for the merchants they board. A processor that keeps a merchant whose product regulators are questioning risks fines and network review.
- Chargeback patterns. Monthly medication programs with dose changes, shipping delays, and prescription denials produce "canceled recurring," "not as described," and "product not received" disputes.
- Volume spikes. Weight-loss programs can grow very quickly. Volume that jumps well past your approved monthly limit often triggers a review on its own.
None of this means a compliant clinic can't get processing. It means the processor will look at your whole operation, not just your website.
How FDA Shortage Changes Affect Semaglutide and Tirzepatide Merchant Accounts
Many compounded GLP-1 programs grew while the branded drugs were in shortage. During a shortage, pharmacies generally have more room to compound versions of an approved drug. Once a drug comes off the shortage list, that room narrows. Compounding may still be possible in limited circumstances, such as a documented clinical need for an individual patient. Routine compounding of close copies of an approved drug faces much tighter limits.
The shortage status of both semaglutide and tirzepatide has changed in recent years. Check current FDA status and guidance directly, and review it with your counsel and pharmacy partner. Don't rely on marketing materials or forum posts.
Any semaglutide or tirzepatide payment processor treats a shortage-list change as a trigger event. Expect some or all of the following:
- An inquiry or attestation request. The processor asks what you sell, who compounds it, and what legal basis your pharmacy relies on.
- A product or website review. Underwriting or risk monitoring checks your site, ads, and checkout for products that may no longer be permitted.
- Changes to your account terms. These can include a new or larger reserve, a lower processing limit, or longer funding delays while the processor evaluates you.
- Termination. Some processors exit the category entirely after a status change, regardless of how an individual clinic operates.
The risk team knows about a status change as soon as it is public. Don't wait for the review to reach you. Send a prompt written response, prepared with your counsel, that answers the likely questions and includes your documentation.
Read the Provider's Policy, Not Forum Threads
Merchants often search for things like "Stripe semaglutide ban" after hearing that a large platform restricts compounded weight-loss drugs. Any provider's policy can change. The only reliable answer is that provider's current published list of restricted businesses and its terms of service. Read them before you apply, and read them again after any regulatory change. For a closer look, see our guide to how Stripe, PayPal, and Square treat telehealth and pharmacy sales.
Marketing Claims That Trigger Card Network Reviews
Your marketing is part of your underwriting file. Risk teams and network monitoring services scan websites, landing pages, and social ads. The claims below commonly prompt a review:
| Risky Claim or Practice | Why It Draws Scrutiny | Lower-Risk Alternative |
|---|---|---|
| Calling a compounded product by a brand-name drug's name, or a "generic" of a brand | Implies FDA approval or equivalence the product doesn't have | Describe it as a compounded medication prepared by a licensed pharmacy |
| "FDA-approved" next to a compounded product | Compounded drugs are not FDA-approved products | State what is true about the pharmacy's licensing and oversight |
| Guaranteed results, specific pounds lost, or timelines | Health and efficacy claims invite regulatory and dispute risk | Explain the program process: consult, provider review, prescription if appropriate |
| "No prescription needed" or "approval guaranteed" | Suggests prescribing without real clinical review | Make clear a licensed provider decides eligibility |
| Prices shown without dose-escalation costs | Leads to "not as described" disputes when the price rises | Show the price for each dose tier up front |
The same logic applies in other regulated categories. A label or disclaimer doesn't cancel out what your marketing actually says. We make the same point in our article on whether "research use only" labels protect a peptide merchant account.
Affiliate and influencer content counts too. If a partner posts a before-and-after video with your discount code, your processor treats it as your claim. Give affiliates written content guidelines and get noncompliant posts taken down.
Compounding Pharmacy Partners: What Underwriters Ask
Underwriters rarely accept "we work with a licensed pharmacy" as an answer. They want to know which pharmacy, what kind, and how prescriptions move through it.
In general terms, compounding partners fall into two broad groups. Patient-specific compounding pharmacies prepare medication against individual prescriptions and are overseen mainly at the state level. FDA-registered outsourcing facilities can prepare medication in larger quantities under a different oversight framework. Federal and state rules determine what each type may compound and when, so the pharmacy type matters to a processor. Ask your pharmacy partner and your counsel to confirm which framework applies to your program.
Be ready to provide:
- The pharmacy's name, license numbers, and the states it is licensed to ship to
- Whether it is a patient-specific compounding pharmacy, an FDA-registered outsourcing facility, or both
- Your written agreement with the pharmacy and who is responsible for dispensing
- How your prescribers are licensed in each patient's state
- Your clinical workflow: intake, provider review, prescription, fulfillment
- How you handle patients who are not prescribed medication, including refunds
- Where the active ingredients come from, if your pharmacy will document it
Clinics that answer these questions in one organized package tend to get through underwriting faster than clinics that answer one question at a time.
Subscription Billing Risks in Weight-Loss Telehealth Payment Processing
Most GLP-1 programs bill monthly, and billing design often decides whether your chargeback ratio stays manageable. Weight-loss telehealth payment processing involves some problems that most other subscription businesses don't face:
- Charging before a prescription decision. If you capture the full program fee at intake and the provider declines the patient, refund promptly and automatically. Where your setup supports it, a better approach is to charge a consult fee first and bill for medication only after the provider approves.
- Dose escalation. Prices often rise as patients move to higher doses. Get clear consent before the new price applies, and send a notice before the first higher charge.
- Shipping and cold-chain issues. Late shipments, or ones that arrive warm, create "not received" and "not as described" disputes. Track every shipment and keep delivery confirmation.
- Hard-to-cancel plans. Patients who stop treatment and can't cancel easily will dispute the charge. Make online cancellation as simple as signing up.
- Expired cards. Failed renewals push some clinics into aggressive retry patterns. A card account updater for recurring billing cuts renewal failures without repeated retry attempts.
State automatic renewal laws also apply to many subscription programs, with requirements for disclosures, consent, and cancellation. Review our state-by-state automatic renewal law compliance map and confirm the details with counsel.
Use a billing descriptor that patients will recognize on a statement, and include a support phone number or URL where your processor allows. For first-time online purchases, 3-D Secure authentication can help reduce fraud-related disputes. It does not address cancellation or product complaints. For storing cards at intake and getting payment consent that holds up in disputes, see our guide to card on file for virtual visits, copays, and no-show fees.
What to Do When Your Processor Terminates You
A termination notice is stressful, and the first few days matter most. Work through these steps:
- Read the notice carefully. Note the effective date, the stated reason, and any reserve or held-funds terms.
- Ask for specifics in writing. Was it a product issue, a chargeback level, a marketing finding, or a category-wide exit? The answer shapes your next application.
- Understand the reserve timeline. Processors commonly hold funds for a period after termination to cover future refunds and chargebacks. Ask how long, and how releases are calculated. Your agreement and the processor's risk review determine release timing.
- Keep serving patients. Refund anyone whose order you can't fulfill. Unfulfilled orders after a termination turn into chargebacks that land on your record.
- Check whether stored cards can move. Some gateways can transfer stored card data to a new PCI DSS–compliant provider. Ask early, because this can take time.
- Find out whether you were added to a termination database. Some terminations place the business and its principals on an industry-shared database that other acquirers check, which affects future applications.
Do not reopen under another business name, run transactions through a different merchant's account, describe your products as something else, or use a merchant category code that doesn't match what you sell. That is transaction laundering or miscoding, and it can bring permanent consequences for you and anyone who helps.
When you reapply, disclose the prior termination and explain what changed. Underwriters respond far better to an honest history that shows corrective action than to a history they discover on their own. Even so, approval after a termination is never assured, particularly if you were placed on a shared termination database.
Building a Backup Plan for Your GLP-1 Telehealth Merchant Account
Even a stable GLP-1 telehealth merchant account can change when regulations do. A backup plan keeps one processor's decision from shutting down your revenue.
Separate, Fully Disclosed Accounts
Some clinics hold more than one merchant account with different acquirers. That is legitimate when each provider knows exactly what you sell, your total volume, and that other accounts exist. Routing transactions between accounts to stay under chargeback thresholds or to hide product lines is not legitimate, and it violates card network rules.
A Gateway That Supports Multiple Accounts
A payment gateway that works with more than one processor, such as NMI or Authorize.net, lets you keep your stored customer cards and recurring schedules in one place. If an account closes, switching to another is far less disruptive.
Documentation Kept Current
Keep an underwriting file you can send within a day:
- Pharmacy agreements and licenses
- Prescriber licensing by state
- Current website and ad screenshots
- Subscription terms and the cancellation flow
- Monthly chargeback and refund reports
- A written summary of how your program responds to regulatory changes
A Provider That Understands the Category
Work with a processor that boards high-risk telehealth on purpose rather than by accident. MannyPay provides high-risk merchant accounts and works with telehealth and online pharmacy businesses. Every account is subject to underwriting, and approval, reserves, and terms depend on your specific program.
Next Steps for Compounded GLP-1 Clinics
Processors don't drop semaglutide clinics at random. They react to regulatory changes, marketing claims, unclear pharmacy relationships, and subscription disputes. The clinics that keep processing tend to share a few habits:
- They keep compliance documentation ready to send.
- They describe their products accurately.
- They bill transparently and make cancellation easy.
- They tell their processor about changes early.
If you want an underwriting review of your current setup or a second, fully disclosed account, request a free merchant account quote. A MannyPay specialist responds within one business day. For general questions, contact the MannyPay team.
This article is for general educational purposes and is not legal, tax or financial advice. Card network rules and state laws change; confirm current requirements for your business.
